Balance Sheet Detail

6 Months Ended

Apr. 27, 2025

Balance Sheet Detail [Abstract]

Balance Sheet Detail

Balance Sheet Detail

 

	April 27, 2025		October 27, 2024
	(In millions)
Inventories
Customer service spares	$	1,752	$	1,742
Raw materials	1,865		1,680
Work-in-process	909		879
Finished goods
Deferred cost of sales	284		217
Evaluation inventory	485		459
Manufactured on-hand inventory	361		444
Total finished goods	1,130		1,120
Total inventories	$	5,656	$	5,421

 

	April 27, 2025		October 27, 2024
	(In millions)
Other Current Assets
Prepaid income taxes and income taxes receivable	$	55	$	120
Prepaid expenses and other	1,063		974
	$	1,118	$	1,094

	Useful Life	April 27, 2025		October 27, 2024
	(In years)	(In millions)
Property, Plant and Equipment, Net
Land and improvements		$	513	$	492
Buildings and improvements	3-30	2,628		2,359
Demonstration and manufacturing equipment	5-8	2,667		2,578
Furniture, fixtures and other equipment	3-5	802		782
Construction in progress		1,116		898
Gross property, plant and equipment		7,726		7,109
Accumulated depreciation		(3,894)		(3,770)
		$	3,832	$	3,339

	April 27, 2025		October 27, 2024
	(In millions)
Deferred Income Taxes and Other Assets
Non-current deferred income taxes	$	1,723	$	2,393
Operating lease right-of-use assets	434		375
Income tax receivables and other assets	300		314
	$	2,457	$	3,082

	April 27, 2025		October 27, 2024
	(In millions)
Accounts Payable and Accrued Expenses
Accounts payable	$	1,803	$	1,570
Compensation and employee benefits	844		1,188
Warranty	370		364
Dividends payable	369		327
Income taxes payable	309		535
Operating lease liabilities, current	81		87
Other	930		749
	$	4,706	$	4,820

 

	April 27, 2025		October 27, 2024
	(In millions)
Other Liabilities
Defined and postretirement benefit plans	$	142	$	142
Operating lease liabilities, non-current	328		259
Other	422		409
	$	892	$	810

Government Assistance

Capital expenditure related incentives reduced gross property, plant and equipment, net by $682 million as of April 27, 2025. Contra-depreciation expense was not material during the three and six months ended April 27, 2025. Operating incentives recognized as a reduction to research, development and engineering expense were $7 million and $18 million in the three and six months ended April 27, 2025, respectively. Capital expenditure related incentives reduced our income taxes payable by $142 million as of April 27, 2025, of which $133 million is in accounts payable and accrued expenses and $9 million is deferred income taxes and other assets, in our Consolidated Condensed Balance Sheets.